Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bionano Genomics, Inc.BNGO · Entity 7831 | Director | June 11, 2025 | June 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bionano Genomics, Inc.
Report date June 11, 2025 · Filed June 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.67 · Expires 2035-06-10 | Direct | 2,775 |
Reported balance
After 2025-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-11 · Grant · Acquired 2,775 · Balance 2,775 F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). |
Filing footnotes · ownership attribution and instrument terms
F1: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2025 Filed Jun 12, 2025 16:50 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 2,775 | $0.00 Strike: $3.67 | $0.00 |
DisclosureSEC source: 0001411690-25-000065 · wk-form4_1749761408.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,775 Underlying: Common Stock · 2,775 shares Expires 2035-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 16:22 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001411690-24-000032 · wk-form4_1718914944.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the option holder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 16:17 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001411690-23-000058 · wf-form4_168694661088294.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 13, 2023 Filed Jun 14, 2023 18:32 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | PurchaseCommon Stock | 65,789 | $0.76 | $49,999.64 |
DisclosureSEC source: 0001411690-23-000034 · wf-form4_168678194063640.xml · nonDerivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,789 Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:32 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 164,422 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001209191-22-036328 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,422 Underlying: Common Stock · 164,422 shares Expires 2032-06-09 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| August 17, 2021 Filed Aug 19, 2021 17:20 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 40,751 | $0.00 Strike: $5.34 | $0.00 |
DisclosureSEC source: 0001209191-21-052586 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,751 Underlying: Common Stock · 40,751 shares Expires 2031-08-17 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following June 10, 2021, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 19:16 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 7,528 | $0.00 Strike: $7.64 | $0.00 |
DisclosureSEC source: 0001209191-21-040404 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 Underlying: Common Stock · 7,528 shares Expires 2031-06-10 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's Continuous Service (as defined in the Company's 2018 equity incentive plan) through each such vesting date and will vest in full upon a Change of Control (as defined in the Company's 2018 equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:31 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-20-040759 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2029-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
| June 30, 2020 Filed Jul 18, 2022 19:25 UTC Amendment | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (Right to Buy) · Derivative | 44,470 | $0.00 Strike: $0.51 | $0.00 |
DisclosureSEC source: 0001209191-22-042480 · doc4a.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,470 Underlying: Common Stock · 44,470 shares Expires 2030-06-30 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). F2 · derivative.expiration_date: The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029. Read SEC document |
| May 04, 2020 Filed May 6, 2020 14:30 UTC | Bionano Genomics, Inc. BNGO · Entity 7831 | GrantStock Option (right to buy) · Derivative | 80,923 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001209191-20-027427 · doc4.xml · derivative · entry 1 Mamuszka Hannah · CIK 0001810929 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,923 Underlying: Common Stock · 80,923 shares Expires 2030-05-04 F1 · derivative.exercise_date: The shares vest in equal monthly installments over a three year period such that the option is fully vested on May 4, 2023, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.